Redefine liver cancer care through clinical evidence
TheraSphere™ Y-90 Therapy is supported by guidelines for effective HCC
management3-6 and remains at the forefront of cancer treatment, continually adding to its robust body of scientific evidence.
Set the standards with SIRT
Together with liver cancer specialists, we advance meaningful outcomes through TheraSphere™ Y-90 Therapy - proven safe and effective across BCLC stages, with 30,000+ patients treated in Europe over two decades.
Explore the key landmark studies below:
| 2026 | PROACTIF |
| The Largest, Prospective, Real-World Y-90 study of Primary Liver Cancer. |
Real-world evidence – Powering insights Beyond Clinical Trials
Real-world studies complement prospective trial data, offering a more complete view of patient outcomes in routine practice. They reflect broader patient populations and support more informed clinical decision-making. By strengthening MDT discussions, real-world evidence helps address unmet needs – particularly where standard algorithms fall short. |
| 2022 | TRACE |
| Evolved Treatment Paradigm | |
| Superior tumour control and survival compared to DEB-TACE. | |
| 2022 | RASER |
| Advanced Precision | |
| Established Radiation Segmentectomy for Curative Intent. | |
| 2022 | TARGET |
| Built Confidence | |
| Real-world data confirming Dose Matters to Improve Survival. | |
| 2021 | LEGACY |
| Changed Guidelines | |
| Established the inclusion of SIRT in BCLC 2022 guidelines. | |
| 2020 | DOSISPHERE-01 |
| Transformed HCC Practice | |
| TheraSphereTM Y-90 Therapy with personalised dosimetry improved objective response rate and overall survival. | |
| 2016 | PREMIERE |
| Bridged to Surgery | |
| Reduced drop out from waiting list. |
TheraSphere™ Y-90 Therapy: A versatile, guideline-endorsed treatment delivering proven results.
Safe and effective across all BCLC stages - from disease control to curative pathways - empowering seamless multimodal, multidisciplinary treatment strategies.
Recommendation | BCLC1 | EASL2 | ESMO3 | ILTS-ILCA4 |
Alternative to TACE | ✔ | ✔ | ✔ | ✔ |
Bridging to Liver Transplant | ✔ | ✔ | ✔ | ✔ |
Bridging to Liver Resection | ✔ | ✔ |
| |
Downstaging to curative surgery | ✔ | ✔ |
| ✔ |
Radiation segmentectomy | ✔ | ✔ | ✔ |
|
Caution:
The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
1. Gabr A, al. Liver Transplantation Following Yttrium‐90 Radioembolization: 15‐year Experience in 207‐Patient Cohort. Hepatology 2021;73(3):998-1010.
2. DOSISPHERE-01: Garin E, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29.
3. Reig M, Sanduzzi-Zamparelli M, Forner A, et al. BCLC strategy for prognosis prediction and treatment recommendations: 2025 update. J Hepatol. 2025
4. EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol. 2024
5. Vogel A, Chan SL, Dawson LA, et al. Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025.*
6. Kodali S, Kulik L, D’Alessio A, et al. ILTS–ILCA consensus recommendations for liver transplantation for hepatocellular carcinoma. Transplantation. AASLD 2025.
*Hepatocellular Carcinoma